Drug And Hormone Resistance In The Management Of Breast Cancer

Author(s):  
Pierre R Band
2014 ◽  
Vol 60 (3) ◽  
pp. 322-331 ◽  
Author(s):  
E.A. Avilova ◽  
O.E. Andreeva ◽  
V.A. Shatskaya ◽  
M.A. Krasilnikov

The main goal of this work was to study the intracellular signaling pathways responsible for the development of hormone resistance and maintaining the autonomous growth of breast cancer cells. In particular, the role of PAK1 (p21-activated kinase 1), the key mitogenic signaling protein, in the development of cell resistance to estrogens was analyzed. In vitro studies were performed on cultured breast cancer cell lines: estrogen-dependent estrogen receptor (ER)-positive MCF-7 cells and estrogen-resistant ER-negative HBL-100 cells. We found that the resistant HBL-100 cells were characterized by a higher level of PAK1 and demonstrated PAK1 involvement in the maintaining of estrogen-independent cell growth. We have also shown PAK1 ability to up-regulate Snail1, one of the epithelial-mesenchymal transition proteins, and obtained experimental evidence for Snail1 importance in the regulation of cell proliferation. In general, the results obtained in this study demonstrate involvement of PAK1 and Snail1 in the formation of estrogen-independent phenotype of breast cancer cells showing the potential role of both proteins as markers of hormone resistance of breast tumors.


2021 ◽  
Vol 5 (1) ◽  
pp. 18
Author(s):  
Lianne Fakes ◽  
Iain Hutcheson ◽  
Janice Knowlden

Metallomics ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1579-1592 ◽  
Author(s):  
Silvia Ziliotto ◽  
Julia M. W. Gee ◽  
Ian O. Ellis ◽  
Andrew R. Green ◽  
Pauline Finlay ◽  
...  

Zinc transporter ZIP7 activates key downstream signalling pathways and is correlated with important clinicopathological parameters that are associated with endocrine resistance.


2020 ◽  
Vol 26 (9) ◽  
pp. 1900-1902
Author(s):  
Wala Ben Kridis ◽  
Ines Werda ◽  
Wafa Mnejja ◽  
Jamel Daoud ◽  
Afef Khanfir

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e77060 ◽  
Author(s):  
Xinyu Wu ◽  
Yirong Li ◽  
Jinhua Wang ◽  
Xin Wen ◽  
Max T. Marcus ◽  
...  

Breast Cancer ◽  
2006 ◽  
Vol 13 (2) ◽  
pp. 137-144 ◽  
Author(s):  
Eriko Tokunaga ◽  
Yasue Kimura ◽  
Kojiro Mashino ◽  
Eiji Oki ◽  
Akemi Kataoka ◽  
...  

2021 ◽  
Vol 7 (3) ◽  
pp. FSO672
Author(s):  
Serafin Morales Murillo ◽  
Ariadna Gasol Cudos ◽  
Joel Veas Rodriguez ◽  
Carles Canosa Morales ◽  
Jordi Melé Olivé ◽  
...  

Background: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer. Discussion: Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.


2013 ◽  
Vol 155 (3) ◽  
pp. 384-395 ◽  
Author(s):  
A. M. Scherbakov ◽  
M. A. Krasil’nikov ◽  
N. E. Kushlinskii

Sign in / Sign up

Export Citation Format

Share Document